Internal Medicine, Gastroenterology · Sugar Land, TX
NPI
1972576346
Since 2006
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
17510 West Grand Parkway South, Suite 350
Sugar Land, TX, 77479
Phone (281) 762-6300
Groups this clinician bills Medicare through
Medicare paid, 2024
$328K
11,444 services
Medicare patients, 2024
580
Average age 73
Drug cost, 2024
$568K
1,892 prescriptions
Company payments, 2025
$805
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Stanley H Stein was code 99215 (office e&m - established), 182 times for 164 patients. In total Stanley H Stein billed 11,444 services in 30 codes, and Medicare paid $328K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-02-05.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 182 | 164 | $121.07 | $22K |
| 99214 Office E&M - Established | Office | 120 | 118 | $84.13 | $10K |
| 99213 Office E&M - Established | Office | 118 | 114 | $59.94 | $7,073 |
| 43239 Upper GI Endoscopy | Facility | 109 | 107 | $62.99 | $6,866 |
| 45380 Lower GI Endoscopy - Other | Facility | 96 | 96 | $137.28 | $13K |
| G0105 Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 88 | 87 | $169.76 | $15K |
| 99202 Office E&M - New | Office | 86 | 86 | $37.12 | $3,192 |
| 99212 Office E&M - Established | Office | 70 | 16 | $41.40 | $2,898 |
| 96413 Chemotherapy Administration | Office | 66 | 11 | $98.08 | $6,473 |
| 99203 Office E&M - New | Office | 58 | 58 | $69.14 | $4,010 |
| 82272 Immunoassay | Office | 56 | 55 | $4.15 | $232 |
| 99204 Office E&M - New | Office | 51 | 51 | $106.82 | $5,448 |
| 45385 Colonoscopy - Lesion Removal | Facility | 50 | 50 | $200.52 | $10K |
| 43249 Upper GI Endoscopy | Facility | 42 | 40 | $96.41 | $4,049 |
| 99205 Office E&M - New | Office | 41 | 41 | $144.33 | $5,918 |
By year: 2022 $342K for 9,397 services; 2023 $307K for 9,566 services; 2024 $328K for 11,444 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82272 Immunoassay | 56 | 55 | $4.15 | $232 |
| 36415 Venipuncture Blood Collection | 31 | 11 | $8.65 | $268 |
Medicare prescription drug claims, 2024
In 2024, the drug Stanley H Stein prescribed most often to Medicare patients was Pantoprazole Sodium, with 650 prescriptions and refills. In total Stanley H Stein wrote 1,892 Medicare prescriptions that cost $568K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Pantoprazole Sodium Generic | 650 | 1,943 | 224 | $10K |
| Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates | 277 | 277 | 274 | $17K |
| Omeprazole Generic | 123 | 351 | 37 | $1,419 |
| Lansoprazole Generic | 97 | 292 | 34 | $2,980 |
| Famotidine Generic | 78 | 228 | 26 | $1,131 |
| Esomeprazole Magnesium Generic | 74 | 219 | 24 | $3,751 |
| Dexlansoprazole Dr Dexlansoprazole | 59 | 169 | 20 | $27K |
| Rabeprazole Sodium Generic | 56 | 160 | 23 | $2,869 |
| Linzess Linaclotide | 41 | 99 | 14 | $51K |
| Mesalamine Generic | 40 | 107 | Under 11 | $30K |
| Mesalamine Er Mesalamine | 36 | 108 | 11 | $42K |
| Cholestyramine Cholestyramine (With Sugar) | 34 | 55 | 14 | $2,799 |
| Dicyclomine Hcl Generic | 26 | 42 | Under 11 | $476 |
| Voquezna Vonoprazan Fumarate | 24 | 32 | Under 11 | $19K |
| Cholestyramine Light Cholestyramine | 18 | 26 | Under 11 | $1,831 |
Brand drugs: - claims; generic drugs: 1,615 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Stanley H Stein $805 ($805 in general payments such as food, travel and fees) from 7 companies. The largest payer was Janssen Biotech, Inc. with $242.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.